Paradromics

Paradromics develops high-data-rate brain-computer interface (BCI) platforms that enable direct exchange of information between the human brain and computers, with the goal of restoring communication and function for people with severe neurological conditions. The company's current product, Connexus BCI, is the fastest BCI in the world and has been recently approved by the FDA for first-in-human clinical studies. Connexus is specifically engineered to restore communication for people who have lost their ability to speak due to conditions such as ALS, spinal cord injury, or stroke. The platform uses high-density electrode arrays that record neural activity at unprecedented data rates, processing brain signals through advanced decoding algorithms to translate intended speech and movement into digital output. Paradromics is also developing Tempo, a pipeline product for additional neurological applications. The company envisions a future where BCIs become seamlessly integrated into conscious experience, delivering brain therapeutics today while unlocking broader human-technology integration capabilities tomorrow. Founded in 2015 and headquartered in Austin, Texas, Paradromics has raised approximately $88.7 million in a Series A round backed by Arkitekt Ventures, Synergy Ventures, IT-Farm Corporation, Dolby Family Ventures, Alpha Edison, Loup Ventures, Fusion Fund, DARPA, and Prime Movers Capital.